This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
KUALA LUMPUR, Aug 15 — Bursa Malaysia closed higher today on continued mild buying in selected heavyweights led by Public Bank, as well as mid and small-cap stocks, amid the weaker trend in most regional peers, dealers said.
PNADF PBLOF 7036 5681 1295 BSMAF PNAGF 6033 1818
KUALA LUMPUR, Aug 14 — Bursa Malaysia extended losses from yesterday to open lower on continued selling pressure, as investor sentiment remained bearish in tracking geopolitical concerns over Turkey, dealers said.
PNADF PBLOF 7036 5681 1295 BSMAF PNAGF 6033 1818
KUALA LUMPUR (Aug 13): The FBM KLCI tumbled 1.13% at the midday break today as sentiment took a beating and key blue chips on Bursa Malaysia fell in tandem with the regional markets.
7036 5246 9334 6033 7123 PNADF 5347 5225 3301 0026 TNABY 5819 TNABF Q0F BSMAF IHHHF PNAGF 1818
KUALA LUMPUR, Aug 13 — Bursa Malaysia was lower almost across-the-board at mid-day today in line with regional peers and dragged down by the crisis facing the Turkish lira, which has fallen sharply against the US dollar, dealers said.
PBLOF 7036 1295 BSMAF 1818
KUALA LUMPUR (Aug 13): The FBM KLCI skidded 0.95% at mid-morning today and dropped to below the 1,800-point level, tracking the weaker regional markets.
UPBMF 7036 BATS 4162 5246 2089 9334 6033 PNADF 5347 5225 0026 TNABY 2836 TNABF Q0F BSMAF IHHHF PNAGF 1818
KUALA LUMPUR, Aug 10 — Bursa Malaysia bucked the trend of most of its Asian peers to stay in positive territory at mid-afternoon today on higher crude oil prices.
0143 PNADF 0026 UPBMF 7036 5681 BSMAF PNAGF 2089 6033 1818 2593
KUALA LUMPUR (Aug 10): The FBM KLCI pared some of its gains at midday today as decliners overtook advancers, tracking the sentiment at most regional markets.
SPMXF UPBMF 7036 5681 BATS 4162 7765 5015 2089 5014 0131 6033 2593 2852 0143 5029 PNADF SPMXY 3883 0026 MYPRY PNAGF GEBHF
KUALA LUMPUR, Aug 7 ― Bursa Malaysia finished its trading on a positive note today, taking the cue from its Asian peers following the overnight rally on Wall Street backed by a strong earnings season.
PNADF PBLOF UPBMF 7036 1295 BSMAF PNAGF 2089 6033 1818
1h - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
1h - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
2h - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...